Director, Medical Affairs, Precision Oncology
Vice President, US Medical Affairs, Precision Oncology
Oral Presentation | Tuesday, 12/6/22 2:00 PM CT
Race and clinical outcomes in the RxPONDER trial (SWOG S1007)
GS10-01 | Abdou
Oral Presentation | Tuesday, 12/6/22 2:45 PM CT
Patient-reported cognitive impairment in women participating in the RxPONDER trial (SWOG S1007) by menopausal status
GS1-04 | Kang
Oral Presentation | Tuesday, 12/6/22 3:00 PM CT
Trial Assigning Individualized Options for Treatment (TAILORx): An Update Including 12-Year Event Rates
GS1-05 | Sparano
Poster Discussion | Wednesday, 12/7/22 9:45-11:00 AM CT (Final talk in session)
Impact of HER2 low status on clinical outcomes in participants (pts) with 1-3 positive lymph nodes (LN), hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with recurrence score (RS) < 25 randomized to endocrine therapy (ET) +/- chemotherapy (CT): results from SWOG S1007 (RxPONDER)
HER2-19 | Spring
